News & Updates

Show Multimedia Only

Ramipril on par with sacubitril/valsartan in acute MI

05 Mar 2024

Combination treatment with sacubitril and valsartan appears to be no better than ramipril in reducing the risk of cardiovascular death and heart failure (HF) in patients with acute myocardial infarction (AMI) complicated by left ventricular dysfunction, regardless of AMI type, reveals a study.

Ramipril on par with sacubitril/valsartan in acute MI

05 Mar 2024

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

05 Mar 2024 by

Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

05 Mar 2024

Nirmatrelvir reduces the risk of long COVID

05 Mar 2024

Post-COVID condition, also known as long COVID, is a serious public health problem affecting millions of people around the world.¹

Nirmatrelvir reduces the risk of long COVID

05 Mar 2024

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

05 Mar 2024 by

Adding lutetium-177 (¹⁷⁷Lu)–Dotatate radioligand therapy (RLT) to long-acting octreotide as first-line therapy significantly improves progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor-positive (SSTR+), grade 2 and 3 (G2 and G3), well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs) compared with high-dose long-acting octreotide alone, according to the NETTER-2 trial presented at ASCO GI 2024.

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

05 Mar 2024

High-dose PPI use among cirrhotic patients poses risk of death, complications

04 Mar 2024

Patients with cirrhosis who are exposed to high-dose proton pump inhibitors (PPIs) are at increased risk of death and cirrhotic complications, as suggested in a retrospective study.

High-dose PPI use among cirrhotic patients poses risk of death, complications

04 Mar 2024

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

04 Mar 2024 by

Treatment with belzutifan helps patients with previously treated advanced renal cell carcinoma (RCC) achieve better disease-specific symptoms and quality of life (QoL) compared with everolimus, according to the patient-reported outcome (PRO) data from the phase III LITESPARK-005 trial.

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

04 Mar 2024

COVID-19 vaccine–related cycle length changes linked to receipt of vaccine during follicular phase

04 Mar 2024

Receipt of the COVID-19 vaccine during the follicular phase of the menstrual cycle leads to changes in cycle length, as reported in a study.

COVID-19 vaccine–related cycle length changes linked to receipt of vaccine during follicular phase

04 Mar 2024

Subcutaneous noninferior to intravenous nivolumab for clear cell renal cell carcinoma

03 Mar 2024 by

Subcutaneous nivolumab is good enough for patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC) when compared with intravenous nivolumab, with no significant differences in the pharmacokinetic, efficacy, and safety endpoints, according to data from the open-label, phase III CheckMate 67T study.